Targeting the brain: Advances in drug delivery

Current Pharmaceutical Biotechnology

Volumn 13, Issue 12, 2012, Pages 2417-2426

  Blumling III, James P ^a   Silva, Gabriel A ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Blood brain barrier; Brain; Central nervous system; Drug delivery; Liposome; Molecular trojan horse; Nanoparticle; Transcranial; Transnasal; Transvascular

Indexed keywords

1,2 DISTEAROYL SN GLYCERO 3 PHOSPHOCHOLINE; 1,2 DISTEAROYL SN GLYCERO 3 PHOSPHOETHANOLAMINE N [METHOXY (POLYETHYLENE GLYCOL) 2000]; ASPARTOACYLASE; CAMPTOTHECIN; CAMPTOTHECIN 11; CARMUSTINE; CELL PENETRATING PEPTIDE; CHONDROITIN SULFATE; COPOLYMER; DOPAMINE; DRUG VEHICLE; ETHYLENE VINYL ACETATE COPOLYMER; FATTY ACID DIMER; GELATIN; INTERLEUKIN 1; INTERLEUKIN 2; KISSPEPTIN; LEVODOPA; LIPOSOME; MACROGOL 2000; MOLECULAR TROJAN HORSE; NERVE GROWTH FACTOR; NEURITE PROMOTING FACTOR; PARVOVIRUS VECTOR; PERFOSFAMIDE; POLYGLACTIN; POLYMER; SEBACIC ACID; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BLOOD BRAIN BARRIER; BRAIN; BRAIN DEGENERATION; BRAIN TUMOR; CONTROLLED DRUG RELEASE; CONVECTION ENHANCED DELIVERY; DRUG DELIVERY SYSTEM; DRUG TARGETING; ECHOGRAPHY; GENE THERAPY; GENETIC TRANSFECTION; GLIOBLASTOMA; HUMAN; IMPLANT; INJECTION; NONHUMAN; PARKINSON DISEASE; SURGICAL RISK; TISSUE NECROSIS; TRANSCYTOSIS; TRANSNASAL DELIVERY; TRANSVASCULAR DELIVERY; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; BRAIN; DRUG ADMINISTRATION ROUTES; DRUG DELIVERY SYSTEMS; HUMANS;

EID: 84867739042     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920112803341833     Document Type: Article

References (116)

1. Abbott, N.J.; R̈onnb̈ack, L.; Hansson, E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat. Rev Neurosci., 2006, 7(1), 41-53.
2. Pardridge, W. Blood-brain barrier delivery. Drug Discov. Today, 2007, 12(1-2), 54-61.
3. Pardridge, W. Blood-brain barrier delivery of protein and non-viral gene therapeutics with molecular Trojan horses. J. Control Release, 2007, 122(3), 345-348.
4. Storkebaum, E.; Lambrechts, D.; Dewerchin, M.; Moreno-Murciano, M.; Appelmans, S.; Oh, H.; Damme, P.V.; Rutten, B.; Man, W.; Mol, M.D. Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat. Neurosci., 2004, 8(1), 85-92.
5. Shoham, S.; Bejar, C.; Kovalev, E.; Weinstock, M. Intracerebroventricular injection of streptozotocin causes neurotoxicity to myelin that contributes to spatial memory decits in rats. Exp. Neurol., 2003, 184(2), 1043-1052.
6. Simoni, M.D.; Sironi, M.; Luigi, A.D.; Manfridi, A.; Mantovani, A.; Ghezzi, P. Intracerebroventricular injection of interleukin 1 induces high circulating levels of interleukin 6. J. Exp. Med., 1990, 171(5), 1773-1777.
7. Irwig, M.; Fraley, G.; Smith, J.; Acohido, B.; Popa, S.; Cunningham, M.; Gottsch, M.; Clifton, D.; Steiner, R. Kisspeptin activation of gonadotropin releasing hormone neurons and regulation of KiSS-1 mRNA in the male rat. Neuroendocrinology, 2005, 80(4), 264-272.
8. Maness, L.; Kastin, A.; Farrell, C.; Banks, W. Fate of leptin after intracerebroventricular injection into the mouse brain. Endocrinology., 1998, 139(11), 4556-4562.
9. Kordower, J.; Emborg, M.; Bloch, J.; Ma, S.; Chu, Y.; Leventhal, L.; McBride, J.; Chen, E.; Pal, S.; Roitberg, B. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science, 2000, 290(5492), 767-773.
10. Matalon, R.; Surendran, S.; Rady, P.; Quast, M.; Campbell, G.; Matalon, K.; Tyring, S.; Wei, J.; Peden, C.; Ezell, E. Adenoassociated virus-mediated aspartoacylase gene transfer to the brain of knockout mouse for canavan disease. Mol. Ther., 2003, 7(5), 580-587.
11. Beer, S.; Hilnger, J.; Davidson, B. Extended release of adenovirus from polymer microspheres: potential use in gene therapy for brain tumors. Adv. Drug Deliv. Rev., 1997, 27(1), 59-66.
12. Mitrophanous, K.; Yoon, S.; Rohll, J.; Patil, D.; Wilkes, F.; Kim, V.; Kingsman, S.; Kingsman, A.; Mazarakis, N. Stable gene transfer to the nervous system using a non-primate lentiviral vector. Gene Ther., 1999, 6(11), 1808-1818.
13. Janson, C.; McPhee, S.; Bilaniuk, L.; Haselgrove, J.; Testaiuti, M.; Freese, A.; Wang, D.; Shera, D.; Hurh, P.; Rupin, J. Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain. Hum. Gene. Ther., 2002, 13(11), 1391-1412.
14. Mamot, C.; Nguyen, J.; Pourdehnad, M.; Hadaczek, P.; Saito, R.; Bringas, J.; Drummond, D.; Hong, K.; Kirpotin, D.; McKnight, T. Extensive distribution of liposomes in rodent brains and brain tumors following convection-enhanced delivery. J. Neuro. Oncolo., 2004, 68(1), 1-9.
15. Bobo, R.; Laske, D.; Akbasak, A.; Morrison, P.; Dedrick, R.; Oldeld, E. Convection-enhanced delivery of macromolecules in the brain. Proc. Natl. Acad. Sci. USA, 1994, 91(6), 2076-2080.
16. MacKay, J.; Deen, D.; Jr, F.S. Distribution in brain of liposomes after convection enhanced delivery; modulation by particle charge, particle diameter, and presence of steric coating. Brain Res., 2005, 1035(2), 139-153.
17. Noble, C.; Krauze, M.; Drummond, D.; Yamashita, Y.; Saito, R.; Berger, M.; Kirpotin, D.; Bankiewicz, K.; Park, J. Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: pharmacology and efcacy. Cancer Res., 2006, 66(5), 2801-2806.
18. Yang, W.; Barth, R.; Adams, D.; Ciesielski, M.; Fenstermaker, R.; Shukla, S.; Tjarks, W.; Caligiuri, M. Convection-enhanced delivery of boronated epidermal growth factor for molecular targeting of EGF receptor-positive gliomas. Cancer Res., 2002, 62(22), 6552-6558.
19. Vogelbaum, M. Convection enhanced delivery for the treatment of malignant gliomas: symposium review. J. Neuro-oncolo., 2005, 73(1), 57-69.
20. Hadaczek, P.; Kohutnicka, M.; Krauze, M.; Bringas, J.; Pivirotto, P.; Cunningham, J.; Bankiewicz, K. Convection-enhanced delivery of adeno-associated virus type 2 (AAV2) into the striatum and transport of AAV2 within monkey brain. Hum. Gene. Ther., 2006, 17(3), 291-302.
21. Cunningham, J.; Pivirotto, P.; Bringas, J.; Suzuki, B.; Vijay, S.; Sanftner, L.; Kitamura, M.; Chan, C.; Bankiewicz, K. Biodistribution of adeno-associated virus type-2 in nonhuman primates after convection-enhanced delivery to brain. Mol. Ther., 2008, 16(7), 1267-1275.
22. Eberling, J.; Jagust, W.; Christine, C.; Starr, P.; Larson, P.; Bankiewicz, K.; Aminoff, M. Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology, 2008, 70(21), 1980-1983.
23. Gill, S.; Patel, N.; Hotton, G.; O'Sullivan, K.; McCarter, R.; Bunnage, M.; Brooks, D.; Svendsen, C.; Heywood, P. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat. Med., 2003, 9(5), 589-595.
24. Fiandaca, M.; Forsayeth, J.; Dickinson, P.; Bankiewicz, K. Imageguided convection-enhanced delivery platform in the treatment of neurological diseases. Neurotherapeutics, 2008, 5(1), 123-127.
25. Langer, R. Polymer implants for drug delivery in the brain. J. Control Release, 1991, 16(1-2), 53-59.
26. Brem, H.; Langer, R. Polymer-based drug delivery to the brain. Sci. Med., 1996, 3, 52-61.
27. Brem, H.; Gabikian, P. Biodegradable polymer implants to treat brain tumors. J. Control Release, 2001, 74(1-3), 63-67.
28. Brem, H.; Tamargo, R.J.; Olivi, A.; Pinn, M.; Weingart, J.D.; Wharam, M.; Epstein, J.I. Biodegradable polymers for controlled delivery of chemotherapy with and without radiation therapy in the monkey brain. J. Neurosurg., 1994, 80(2), 283-290.
29. Guerin, C.; Olivi, A.; Weingart, J.; Lawson, H.; Brem, H. Recent advances in brain tumor therapy: local intracerebral drug delivery by polymers. Invest. New Drug, 2004, 22(1), 27-37.
30. Sipos, E.; Tyler, B.; Piantadosi, S.; Burger, P.; Brem, H. Optimizing interstitial delivery of BCNU from controlled release polymers for the treatment of brain tumors. Cancer Chemoth Pharm., 1997, 39(5), 383-389.
31. Tamargo, R.; Epstein, J.; Reinhard, C.; Chasin, M.; Brem, H. Brain biocompatibility of a biodegradable, controlled-release polymer in rats. J. Biomed. Mater Res., 2004, 23(2), 253-266.
32. Brem, H.; Domb, A.; Lenartz, D.; Dureza, C.; Olivi, A.; Epstein, J. Brain biocompatibility of a biodegradable controlled release polymer consisting of anhydride copolymer of fatty acid dimer and sebacic acid. J. Control Release, 1992, 19(1-3), 325-329.
33. Buahin, K.; Judy, K.; Hartke, C.; Domb, A.; Maniar, M.; Colvin, O.; Brem, H. Controlled release of 4hydroperoxycyclophosphamide from the fatty acid dimer-sebacic acid copolymer. Polym. Adv. Technol., 2003, 3(6), 311-316.
34. Hanes, J.; Sills, A.; Zhao, Z.; Suh, K.; Tyler, B.; DiMeco, F.; Brat, D.; Choti, M.; Leong, K.; Pardoll, D. Controlled local delivery of interleukin-2 by biodegradable polymers protects animals from experimental brain tumors and liver tumors. Pharm. Res., 2001, 18(7), 899-906.
35. Krewson, C.E.; Dause, R.; Mak, M.; Saltzman, W.M. Stabilization of nerve growth factor in controlled release polymers and in tissue. J. Biomater. Sci. Polym. Ed., 1996, 8(2), 103-117.
36. Tamargo, R.; Rossell, L.; Kossoff, E.; Tyler, B.; Ewend, M.; Aryanpur, J. The intracerebral administration of phenytoin using controlled-release polymers reduces experimental seizures in rats. Epilepsy Res., 2002, 48(3), 145-155.
37. Frazier, J.; Pradilla, G.; Wang, P.; Tamargo, R. Inhibition of cerebral vasospasm by intracranial delivery of ibuprofen from a controlled-release polymer in a rabbit model of subarachnoid hemorrhage. J. Neurosurg. Pediatr., 2004, 101(1), 93-98.
38. Gabikian, P.; Clatterbuck, R.; Eberhart, C.; Tyler, B.; Tierney, T.; Tamargo, R. Prevention of experimental cerebral vasospasm by intracranial delivery of a nitric oxide donor from a controlled-release polymer: toxicity and efcacy studies in rabbits and rats. Stroke., 2002, 33(11), 2681-2686.
39. Graff, C.; Pollack, G. Nasal drug administration: potential for targeted central nervous system delivery. J. Pharm. Sci., 2005, 94(6), 1187-1195.
40. Illum, L. Nasal drug delivery: new developments and strategies. Drug Discov. Today, 2002, 7(23), 1184-1189.
41. Illum, L. Nasal drug delivery-possibilities, problems and solutions. J. Control Release, 2003, 87(1-3), 187-198.
42. Dahlin, M.; Bergman, U.; Jansson, B.; Bj̈ork, E.; Brittebo, E. Transfer of dopamine in the olfactory pathway following nasal administration in mice. Pharm Res., 2000, 17(6), 737-742.
43. Oh, Y.; Kim, J.; Hwang, T.; Ko, J.; Kim, J.; Yang, J.; Kim, C. Nasal absorption and biodistribution of plasmid DNA: an alternative route of DNA vaccine delivery. Vaccine, 2001, 19(31), 4519-4525.
44. Gross, E.; Swenberg, J.; Fields, S.; Popp, J. Comparative morphometry of the nasal cavity in rats and mice. J. Anat., 1982, 135(Pt 1), 83-88.
45. Davis, S.; Illum, L. Absorption enhancers for nasal drug delivery. Clin. Pharmacokinet., 2003, 42(13), 1107-1128.
46. Ugwoke, M.; Agu, R.; Verbeke, N.; Kinget, R. Nasal mucoadhesive drug delivery: Background, applications, trends and future perspectives. Adv. Drug Deliv. Rev., 2005, 57(11), 1640-1665.
47. Zhang, Q.; Jiang, X.; Jiang, W.; Lu, W.; Su, L.; Shi, Z. Preparation of nimodipine-loaded microemulsion for intranasal delivery and evaluation on the targeting efciency to the brain. Int. J pharmaceut., 2004, 275(1-2), 85-96.
48. Vyas, T.; Babbar, A.; Sharma, R.; Singh, S.; Misra, A. Intranasal mucoadhesive microemulsions of clonazepam: Preliminary studies on brain targeting. J. Pharm. Sci., 2006, 95(3), 570-581.
49. Kumar, M.; Misra, A.; Babbar, A.; Mishra, A.; Mishra, P.; Pathak, K. Intranasal nanoemulsion based brain targeting drug delivery system of risperidone. Int. J. pharmaceut., 2008, 358(1-2), 285-291.
50. Gao, X.; Tao, W.; Lu, W.; Zhang, Q.; Zhang, Y.; Jiang, X.; Fu, S. Lectin-conjugated PEG-PLA nanoparticles: preparation and brain delivery after intranasal administration. Biomaterials., 2006, 27(18), 3482-3490.
51. Pardridge, W. Drug delivery to the brain. J. Cereb Blood F. Met., 1997, 17(7), 713-731.
52. Abbott, N.J. Inammatory mediators and modulation of blood-brain barrier permeability. Cell Mol. Neurobiol., 2000, 20(2), 131-147.
53. Vykhodtseva, N.; McDannold, N.; Hynynen, K. Progress and problems in the application of focused ultrasound for blood-brain barrier disruption. Ultrasonics, 2008, 48(4), 279-296.
54. Yin, X.; Hynynen, K. A numerical study of transcranial focused ultrasound beam propagation at low frequency. Phys. Med. Biol., 2005.
55. Sun, J.; Hynynen, K. The potential of transskull ultrasound therapy and surgery using the maximum available skull surface area. J. Acoust. Soc. Am., 1999, 105, 2519.
56. Kinoshita, M.; McDannold, N.; Jolesz, F.; Hynynen, K. Targeted delivery of antibodies through the blood-brain barrier by MRIguided focused ultrasound. Bioche. Bioph. Res. Co., 2006, 340(4), 1085-1090.
57. Hertzberg, Y.; Volovick, A.; Zur, Y.; Medan, Y.; Vitek, S.; Navon, G. Ultrasound focusing using magnetic resonance acoustic radiation force imaging: Application to ultrasound transcranial therapy. Med. Phys., 2010, 37, 2934.
58. Aubry, J.; Tanter, M.; Pernot, M.; Thomas, J.; Fink, M. Experimental demonstration of noninvasive transskull adaptive focusing based on prior computed tomography scans. J. Acoust. Soc. Am., 2003, 113, 84-93.
59. Allen, D.D.; Lockman, P.R. The blood-brain barrier choline transporter as a brain drug delivery vector. Life Sci., 2003, 73(13), 1609-1615.
60. Takada, Y.; Vistica, D.; Greig, N.; Purdon, D.; Rapoport, S.; Smith, Q. Rapid high-afnity transport of a chemotherapeutic amino acid across the blood-brain barrier. Cancer Res., 1992, 52(8), 2191-2196.
61. Tsuji, A. Small molecular drug transfer across the blood-brain barrier via carrier-mediated transport systems. NeuroRx., 2005, 2(1), 54-62.
62. Begley, D.J. ABC transporters and the blood-brain barrier. Curr. Pharm. Design., 2004, 10(12), 1295-312.
63. Ohtsuki, S.; Terasaki, T. Contribution of carrier-mediated transport systems to the blood-brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development. Pharm. Res., 2007, 24(9), 1745-1758.
64. Sadeque, A.; Wandel, C.; He, H.; Shah, S.; Wood, A. Increased drug delivery to the brain by P-glycoprotein inhibition&ast. Clin. Pharmacol. Ther., 2000, 68(3), 231-237.
65. Kemper, E.; van Zandbergen, A.; Cleypool, C.; Mos, H.; Boogerd, W.; Beijnen, J.; van Tellingen, O. Increased penetration of paclitaxel into the brain by inhibition of P-glycoprotein. Clin. Cancer Res., 2003, 9(7), 2849-2855.
66. Edwards, J.; Brouwer, K.; McNamara, P. GF120918, a Pglycoprotein modulator, increases the concentration of unbound amprenavir in the central nervous system in rats. Antimicrob. Agents Ch., 2002, 46(7), 2284-2286.
67. Imbert, F.; Jardin, M.; Fernandez, C.; Gantier, J.; Dromer, F.; Baron, G.; Mentre, F.; van Beijsterveldt, L.; Singlas, E.; Gimenez, F. Effect of efux inhibition on brain uptake of itraconazole in mice infected with Cryptococcus neoformans. Drug Metab. Dispos., 2003, 31(3), 319-325.
68. Szaḱaradi, A.; acs, G.; V́Ozvegy-Laczka, C.; Sarkadi, B. The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox). Drug Discov. Today, 2008, 13(9-10), 379-393.
69. Pardridge, W. Drug and gene targeting to the brain with molecular Trojan horses. Nat. Rev. Drug Discov., 2002, 1(2), 131-139.
70. Kumar, P.; Wu, H.; McBride, J.; Jung, K.; Kim, M.; Davidson, B.; Lee, S.; Shankar, P.; Manjunath, N. Transvascular delivery of small interfering RNA to the central nervous system. Nature, 2007, 448(7149), 39-43.
71. Kreuter, J. Nanoparticulate systems for brain delivery of drugs. Adv. Drug Deliv. Rev., 2001, 47(1), 65-81.
72. Kurakhmaeva, K.B.; Djindjikhashvili, I.A.; Petrov, V.E.; Balabanyan, V.U.; Voronina, T.A.; Tromov, S.S.; Kreuter, J.; Gelperina, S.; Begley, D.; Alyautdin, R.N. Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles. J. Drug Target, 2009, 17(8), 564-574.
73. Dehouck, B.; Fenart, L.; Dehouck, M.P.; Pierce, A.; Torpier, G.; Cecchelli, R. A new function for the LDL receptor: transcytosis of LDL across the blood-brain barrier. J. Cell Biol., 1997, 138(4), 877-889.
74. Calvo, P.; Gouritin, B.; Chacun, H.; Desmäele, D.; D'Angelo, J.; Noel, J.; Georgin, D.; Fattal, E.; Andreux, J.; Couvreur, P. Longcirculating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharm. Res., 2001, 18(8), 1157-1166.
75. Koziara, J.M.; Lockman, P.R.; Allen, D.D.; Mumper, R.J. Paclitaxel nanoparticles for the potential treatment of brain tumors. J. Control Release, 2004, 99(2), 259-269.
76. Koziara, J.M.; Lockman, P.R.; Allen, D.D.; Mumper, R.J. In situ blood-brain barrier transport of nanoparticles. Pharm. Res., 2003, 20(11), 1772-1778.
77. Blasi, P.; Giovagnoli, S.; Schoubben, A.; Ricci, M.; Rossi, C. Solid lipid nanoparticles for targeted brain drug delivery. Adv. Drug Deliv. Rev., 2007, 59(6), 454-477.
78. Vinogradov, S.V.; Batrakova, E.V.; Kabanov, A.V. Nanogels for oligonucleotide delivery to the brain. Bioconjug Chem., 2004, 15(1), 50-60.
79. Lee, H.; Engelhardt, B.; Lesley, J.; Bickel, U.; Pardridge, W. Targeting rat anti-mouse transferrin receptor monoclonal antibodies through blood-brain barrier in mouse. J. Pharmacol. Exp. Ther., 2000, 292(3), 1048-1052.
80. Pardridge, W.M.; Buciak, J.L.; Friden, P.M. Selective transport of an anti-transferrin receptor antibody through the blood-brain barrier in vivo. J. Pharmacol. Exp. Ther., 1991, 259(1), 66-70.
81. Pardridge, W.; Kang, Y.; Buciak, J.; Yang, J. Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood-brain barrier in vivo in the primate. Pharm. Res., 1995, 12(6), 807-816.
82. Coloma, M.; Lee, H.; Kurihara, A.; Landaw, E.; Boado, R.; Morrison, S.; Pardridge, W. Transport across the primate blood-brain barrier of a genetically engineered chimeric monoclonal antibody to the human insulin receptor. Pharm. Res., 2000, 17(3), 266-274.
83. Boado, R.; Zhang, Y.; Zhang, Y.; Pardridge, W. Humanization of antihuman insulin receptor antibody for drug targeting across the human blood-brain barrier. Biotechnol. Bioeng., 2007, 96(2), 381-391.
84. Pardridge, W. shRNA and siRNA delivery to the brain. Adv. Drug Deliv. Rev., 2007, 59(2-3), 141-152.
85. Boado, R.J. Blood-brain barrier transport of non-viral gene and RNAi therapeutics. Pharm. Res., 2007, 24(9), 1772-1787.
86. Lichota, J.; Skjørringe, T.; Thomsen, L.; Moos, T. Macromolecular drug transport into the brain using targeted therapy. J. Neurochem., 2010, 113(1), 1-13.
87. Zhang, Y.; Pardridge, W. Near complete rescue of experimental parkinson's disease with intravenous, non-viral GDNF gene therapy. Pharm. Res., 2009, 26(5), 1059-1063.
88. Zhang, Y.; Calon, F.; Zhu, C.; Boado, R.; Pardridge, W. Intravenous nonviral gene therapy causes normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism. Hum. Gene. Ther., 2003, 14(1), 1-12.
89. Zhang, Y.; Schlachetzki, F.; Zhang, Y.; Boado, R.; Pardridge, W. Normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism with intravenous nonviral gene therapy and a brain-specic promoter. Hum. Gene. Ther., 2004, 15(4), 339-350.
90. Xia, C.; Chu, C.; Li, J.; Wang, Y.; Zhang, Y.; Boado, R.; Pardridge, W. Comparison of cDNA and genomic forms of tyrosine hydroxylase gene therapy of the brain with Trojan horse liposomes. J. Gene. Med., 2007, 9(7), 605-612.
91. Zhang, Y.; Schlachetzki, F.; Pardridge, W. Global non-viral gene transfer to the primate brain following intravenous administration. Mol. Ther., 2003, 7(1), 11-18.
92. Zhang, Y.; Wang, Y.; Boado, R.; Pardridge, W. Lysosomal enzyme replacement of the brain with intravenous non-viral gene transfer. Pharm. Res., 2008, 25(2), 400-406.
93. Zhang, Y.; Zhang, Y.; Bryant, J.; Charles, A.; Boado, R.; Pardridge, W. Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer. Clin. Cancer Res., 2004, 10(11), 3667.
94. Xia, C.; Zhang, Y.; Zhang, Y.; Boado, R.; Pardridge, W. Intravenous siRNA of brain cancer with receptor targeting and avidin-biotin technology. Pharm. Res., 2007, 24(12), 2309-2316.
95. Suzuki, T.; Wu, D.; Schlachetzki, F.; Li, J.; Boado, R.; Pardridge, W. Imaging endogenous gene expression in brain cancer in vivo with 111In-peptide nucleic acid antisense radiopharmaceuticals and brain drug-targeting technology. J. Nucl. Med., 2004, 45(10), 1766-1775.
96. Huwyler, J.; Wu, D.; Pardridge, W. Brain drug delivery of small molecules using immunoliposomes. Proc. Natl. Acad. Sci. USA, 1996, 93(24), 14164-14169.
97. Huwyler, J.; Yang, J.; Pardridge, W. Receptor mediated delivery of daunomycin using immunoliposomes: pharmacokinetics and tissue distribution in the rat. J. Pharmacol. Exp. Ther., 1997, 282(3), 1541-1546.
98. Cerletti, A.; Drewe, J.; Fricker, G.; Eberle, A.; Huwyler, J. Endocytosis and transcytosis of an immunoliposome-based brain drug delivery system. J. Drug Target, 2000, 8(6), 435-446.
99. Pang, Z.; Lu, W.; Gao, H.; Hu, K.; Chen, J.; Zhang, C.; Gao, X.; Jiang, X.; Zhu, C. Preparation and brain delivery property of biodegradable polymersomes conjugated with OX26. J. Control Release, 2008, 128(2), 120-127.
100. Wu, D.; Song, B.; Vinters, H.; Pardridge, W. Pharmacokinetics and brain uptake of biotinylated basic αbroblast growth factor conjugated to a blood-brain barrier drug delivery system. J. Drug Target, 2002, 10(3), 239-245.
101. Song, B.; Vinters, H.; Wu, D.; Pardridge, W. Enhanced neuroprotective effects of basic αbroblast growth factor in regional brain ischemia after conjugation to a blood-brain barrier delivery vector. J. Pharmacol. Exp. Ther., 2002, 301(2), 605-610.
102. Zhang, Y.; Pardridge, W.M. Conjugation of brain-derived neurotrophic factor to a blood-brain barrier drug targeting system enables neuroprotection in regional brain ischemia following intravenous injection of the neurotrophin. Brain Res., 2001, 889(1-2), 49-56.
103. Zhang, Y.; Pardridge, W.; Keep, R. Neuroprotection in transient focal brain ischemia after delayed intravenous administration of brain-derived neurotrophic factor conjugated to a blood-brain barrier drug targeting system editorial comment. Stroke, 2001, 32(6), 1378-1384.
104. Boado, R.J.; Zhang, Y.; Zhang, Y.; Wang, Y.; Pardridge, W.M. GDNF fusion protein for targeted-drug delivery across the human blood-brain barrier. Biotechnol. Bioeng., 2008, 100(2), 387-396.
105. Zhou, Q.; Boado, R.; Lu, J.; Hui, E.; Pardridge, W. Monoclonal Antibody-Glial-Derived Neurotrophic Factor Fusion Protein Penetrates the Blood-Brain Barrier in the Mouse. Drug Metab. Dispos., 2010, 38(4), 566-572.
106. Boado, R.J.; Zhang, Y.; Zhang, Y.; Xia, C.F.; Pardridge, W.M. Fusion antibody for Alzheimer's disease with bidirectional transport across the blood-brain barrier and abeta bril disaggregation. Bioconjug. Chem., 2007, 18(2), 447-455.
107. Ter-Avetisyan, G.; T̈unnemann, G.; Nowak, D.; Nitschke, M.; Herrmann, A.; Drab, M.; Cardoso, M. Cell entry of arginine-rich peptides is independent of endocytosis. J. Biol. Chem., 2009, 284(6), 3370-3378.
108. Richard, J.; Melikov, K.; Vives, E.; Ramos, C.; Verbeure, B.; Gait, M.; Chernomordik, L.; Lebleu, B. Cell-penetrating peptides. J. Biol. Chem., 2003, 278(1), 585-590.
109. Brooks, H.; Lebleu, B.; Vives, E. Tat peptide-mediated cellular delivery: back to basics. Adv. Drug Deliv. Rev., 2005, 57(4), 559-577.
110. Stewart, K.; Horton, K.; Kelley, S. Cell-penetrating peptides as delivery vehicles for biology and medicine. Org. Biomol. Chem., 2008, 6(13), 2242-2255.
111. Liu, L.; Venkatraman, S.S.; Yang, Y.Y.; Guo, K.; Lu, J.; He, B.; Moochhala, S.; Kan, L. Polymeric micelles anchored with TAT for delivery of antibiotics across the blood-brain barrier. Biopolymers, 2008, 90(5), 617-623.
112. Schwarze, S.; Ho, A.; Vocero-Akbani, A.; Dowdy, S. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science, 1999, 285(5433), 1569-1572.
113. Kilic, E.; Dietz, G.; Hermann, D.; B̈ahr, M. Intravenous TAT-Bcl-Xl is protective after middle cerebral artery occlusion in mice. Ann. Neurol., 2002, 52(5), 617-622.
114. Dietz, G.; Valbuena, P.; Dietz, B.; Meuer, K.; M̈uller, P.; Weishaupt, J.; B̈ahr, M. Application of a bloodbrain-barrierpenetrating form of GDNF in a mouse model for Parkinson's disease. Brain Res., 2006, 1082(1), 61-66.
115. Santra, S.; Yang, H.; Stanley, J.; Holloway, P.; Moudgil, B.; Walter, G.; Mericle, R. Rapid and effective labeling of brain tissue using TAT-conjugated CdS:Mn/ZnS quantum dots. Chem. Commun., 2005, 2005(25), 3144-3146.
116. Liu, L.; Guo, K.; Lu, J.; Venkatraman, S.; Luo, D.; Ng, K.; Ling, E.; Moochhala, S.; Yang, Y. Biologically active core/shell nanoparticles self-assembled from cholesterol-terminated PEG-TAT for drug delivery across the blood-brain barrier. Biomaterials, 2008, 29(10), 1509-1517.